We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Evolus Inc | NASDAQ:EOLS | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.095 | 0.71% | 13.395 | 13.36 | 13.43 | 13.50 | 13.31 | 13.31 | 34,759 | 14:50:20 |
From May 2019 to May 2024
By Colin Kellaher
Shares of Evolus Inc. fell more than 40% in premarket trading Tuesday after the company and its partner Daewoong Pharmaceutical Co. lost an early round in their trade dispute with AbbVie Inc.'s Allergan and its partner Medytox.
On Monday, Evolus said the administrative law judge overseeing the U.S. International Trade Commission case brought by Allergan and Medytox found a violation of the unfair practices section of the Tariff Act of 1930.
Allergan and Medytox filed the complaint last year seeking to block U.S. imports of Jeuveau, a rival to Allergan's Botox, claiming it was developed using stolen manufacturing secrets.
Evolus said it disagrees with the initial determination and that it will seek a review by the full commission, adding that the ITC's final determination is targeted for Nov. 6.
Shares of Evolus, which closed Monday at $5.32, were down 41% to $3.14 in premarket trading Tuesday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 07, 2020 09:27 ET (13:27 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Evolus Chart |
1 Month Evolus Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
